Journal
CANCER RESEARCH
Volume 76, Issue 14, Pages 4136-4148Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-15-3121
Keywords
-
Categories
Funding
- MRC [MR/L017172/1] Funding Source: UKRI
- Cancer Research UK [C491/A15951] Funding Source: Medline
- Medical Research Council [MR/L017172/1] Funding Source: Medline
- Cancer Research UK [18161, 18158, 15951, 22795] Funding Source: researchfish
- Cancer Research UK
- Versus Arthritis [18892] Funding Source: researchfish
- Medical Research Council [1483698, MR/L017172/1] Funding Source: researchfish
- Versus Arthritis
- Cancer Research UK [20613] Funding Source: researchfish
Ask authors/readers for more resources
Antibodies that block T-cell-regulatory checkpoints have recently emerged as a transformative approach to cancer treatment. However, the clinical efficacy of checkpoint blockade depends upon inherent tumor immunogenicity, with variation in infiltrating T cells contributing to differences in objective response rates. Here, we sought to understand the molecular correlates of tumor-infiltrating T lymphocytes (TIL) in squamous cell carcinoma (SCC), using a systems biologic approach to integrate publicly available omics datasets with histopathologic features. We provide evidence that links TIL abundance and therapeutic outcome to the regulation of tumor glycolysis by EGFR and HIF, both of which are attractive molecular targets for use in combination with immunotherapeutics. (C)2016 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available